Compare H World Group Limited American Depositary Shares (HTHT) vs Spyre Therapeutics Inc. Common Stock (SYRE) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
H World Group Limited American Depositary Shares vs Spyre Therapeutics Inc. Common Stock — how do they compare? H World Group Limited American Depositary Shares trades at $44.2 (market cap $14.16B), while Spyre Therapeutics Inc. Common Stock trades at $78.63 (market cap $7.52B). The key difference: H World Group Limited American Depositary Shares is the larger of the two by market cap, and H World Group Limited American Depositary Shares pays a 4.91% dividend while Spyre Therapeutics Inc. Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold H World Group Limited American Depositary Shares for 6 Days and Spyre Therapeutics Inc. Common Stock for 0 Days on average.
| HTHT | SYRE | |
|---|---|---|
Market Cap | $14.16B | $7.52B |
Volume | 1,525,108 | 1,441,031 |
Sector | Consumer Cyclical | Health |
52-Week High | $56.06 | $108.92 |
52-Week Low | $36.99 | $22.18 |
Typical Hold Time | 6 Days | 0 Days |
Enterprise Value | $16.95B | $6.52B |
Dividend Yield | 4.91% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
HTHT trades at $44.17, down 0.85% on the day, with a bullish technical signal supported by moving averages. The company reported strong earnings beats in recent quarters, with Q2 2026 EPS of $0.78 exceeding the $0.74 estimate. Revenue for 2025 was $25.31 billion, with a net income margin of 18.93% and robust ROE of 38.39%. Positive news highlights the asset-light model's margin improvement and a recent CNY bond offering.
The outlook remains positive with a consensus price target of $50.56, implying 14.5% upside, supported by earnings momentum and operational efficiency. Key risks include market saturation in China and reliance on domestic growth. Analyst sentiment is bullish with 11 buy ratings out of 19, though valuation multiples like a P/E of 31.46 warrant monitoring.
SYRE trades at $80.45, down 6.34% over 24 hours, with technical indicators showing neutral momentum near key support at $79. The clinical-stage biotech shows no revenue but maintains strong analyst support (92% buy rating) with a $119.89 consensus target. Recent positive SPY003 phase II ulcerative colitis data (Zacks, 2026-09-09) and a $350 million public offering (GlobeNewsWire, 2026-10-05) provide catalysts, though financials reflect pre-revenue challenges with a -197.71% net margin.
Investment outlook balances high-risk, high-reward potential. The robust pipeline in inflammatory bowel disease offers substantial upside if clinical successes continue, but the absence of revenue, negative cash flow from operations, and reliance on financing pose significant risks. Near-term price action will hinge on Q3 2026 earnings and further clinical updates.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About H World Group Limited American Depositary Shares
H World Group operates hotels through leased and owned, managed franchise, and franchise models. Its brands include HanTing, JI Hotel, Orange Hotel, and Steigenberger Hotels & Resorts.
Read more on HTHT →About Spyre Therapeutics Inc. Common Stock
Spyre Therapeutics develops extended half-life antibody therapies for inflammatory bowel disease, including ulcerative colitis and Crohn's disease. Its pipeline targets pathways such as α4β7, TL1A, and IL-23 with antibodies engineered for infrequent subcutaneous dosing and potential combination use.
Read more on SYRE →
